-
Mashup Score: 19
PURPOSELong-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration.METHODSA multimodal artificial intelligence (…
Source: ascopubs.orgCategories: General Medicine NewsTweet
-
Mashup Score: 19
PURPOSELong-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration.METHODSA multimodal artificial intelligence (…
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Development & Validation of an #ArtificialIntelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy & Radiotherapy in Men W High-Risk #ProstateCancer Across Multiple Phase III Trials: https://t.co/rc789Kw8Qp Authored by @AarmstrongDuke et al #pcsm
-
-
Mashup Score: 8
PURPOSETo our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor (EGFR) mutations….
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell #LungCancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. #lcsm #NSCLC https://t.co/G6EN8DyOX1
-
-
Mashup Score: 15Trials in Progress: The Power of Timely Cancer Clinical Trial Communication | JCO Oncology Advances - 7 day(s) ago
Cancer clinical trials represent a critical mechanism to advance the fields of hematology and oncology. Every US Food and Drug Administration (FDA)-approved cancer treatment has made its way through the pathway of drug development from preclinical studies through clinical trials, to FDA review and approval. Yet, the broader scientific community and public may not learn about cancer clinical trials until after they are completed. We aim to change that. We are introducing a new article type in JCO Oncology
Source: ascopubs.orgCategories: General Medicine NewsTweet-
New article alert! 📢 Read "Trials in Progress: The Power of Timely Cancer Clinical Trial Communication" in #JCOOA by @PamelaKunzMD and get inspired to submit your randomized phase II and phase III Trial in Progress. Read full article. https://t.co/WxqoxgV7Nb
-
-
Mashup Score: 3
PURPOSEThe aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety of sequential umbilical cord–derived mesenchymal stem cell (UC-MSC) infusion for graft-versus-host disease (GVHD) prevention within 3 …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial. Read full article. https://t.co/wEPcg78B7G
-
-
Mashup Score: 3
PURPOSERadiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLAL2 (ClinicalTrials.gov identifier: NCT02354274) used a …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. #NSCLC https://t.co/mUJI5WqCS9
-
-
Mashup Score: 8
PURPOSEDefinitive radiotherapy (RT) for head and neck cancer (HNC) has significant long-term toxicity with elective neck irradiation (ENI) as a major contributor. In this multicenter randomized trial, the clinical benefit and safety of definitive RT with …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. #hncsm Read more. https://t.co/rv8XzmWHXW
-
-
Mashup Score: 5Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment - 10 day(s) ago
PURPOSESurvival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this study were to evaluate prognostic factors for patients with …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment. Co-authored by @SalahDajaniMD https://t.co/8QrfklD3LO
-
-
Mashup Score: 1
Welcome! You are invited to join a webinar: TAPUR Study Grand Rounds 2025. After registering, you will receive a confirmation email about joining the webinar.
Source: asco1.zoom.usCategories: General Medicine NewsTweet-
Join us for the TAPUR Study Grand Rounds on May 6! Learn more about TAPUR Study results and impact with experts @DrLauraPorte and @CarmenCalfa & engage with members of the oncology community. Register now: https://t.co/YKH4tTBsDw https://t.co/MhxoVidCOu
-
-
Mashup Score: 2JCO Oncology Advances | ASCO Publications - 10 day(s) ago
Open Access EDITORIALS Apr 17, 2025 Open Access TRIALS IN PROGRESS Apr 17, 2025 JCO Oncology Advances (JCO OA) is a fully open-access, online-only, and interdisciplinary journal committed to accelerating progress in the global fight against cancer. Open Access TRIALS IN PROGRESS Apr 17, 2025 Open Access EDITORIALS Apr 17, 2025 Open Access REVIEW ARTICLES Apr 16, 2025 Open Access ORIGINAL REPORTS Apr 03, 2025 Open Access ORIGINAL REPORTS Mar 14, 2025 Open Access ORIGINAL REPORTS Mar 14, 2025 Trial-adjac
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Big news for cancer researchers! JCO Oncology Advances is introducing "Trials in Progress" —a new article type to share details of ongoing phase II/III randomized clinical trials from NCTN & academic groups. #CancerResearch Learn more: https://t.co/FF7jTy2bf2 https://t.co/gZ8mUGWRKC
-
Development & Validation of an #ArtificialIntelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy & Radiotherapy in Men W High-Risk #ProstateCancer Across Multiple Phase III Trials: https://t.co/rc789Kw8Qp Authored by @AarmstrongDuke et al #pcsm